{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:29:35Z","timestamp":1780550975376,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.eururo.2021.03.014","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T23:04:15Z","timestamp":1616886255000},"page":"149-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab"],"prefix":"10.1016","volume":"80","author":[{"given":"Andrea","family":"Necchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Dabbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan A.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2021.03.014_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-019-0609-6","article-title":"Treatment approaches for cisplatin-ineligible patients with invasive bladder cancer","volume":"20","author":"Einstein","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eururo.2014.01.009","article-title":"Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides","volume":"67","author":"Reardon","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0020","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2021.03.014_bib0025","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0035","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urolonc.2019.11.004","article-title":"Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy","volume":"38","author":"Grivas","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0040","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The Cancer Genome Atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability","volume":"75","author":"Kim","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0045","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0050","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2021.03.014_bib0055","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","article-title":"Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"25","author":"Seiler","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.014_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2019.06.020","article-title":"Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy","volume":"37","author":"Hensley","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0065","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2021.03.014_bib0070","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.014_bib0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-019-0669-z","article-title":"Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis","volume":"11","author":"de Jong","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.eururo.2021.03.014_bib0080","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2021.03.014_bib0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sjodahl","year":"2017","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0095","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-18-3558","article-title":"Molecular characterization of neuroendocrine-like bladder cancer","volume":"25","author":"Batista da Costa","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.014_bib0100","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2021.03.014_bib0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.urolonc.2019.12.019","article-title":"Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only","volume":"38","author":"Cajipe","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0110","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.juro.2015.10.133","article-title":"Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer\u2014does pT0 predict better survival than pTa\/Tis\/T1?","volume":"195","author":"Zargar","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13046-020-01611-0","article-title":"Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways","volume":"39","author":"Yoshida","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.eururo.2021.03.014_bib0120","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2021.03.014_bib0125","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2020.38.15_suppl.5000","article-title":"IMvigor010: primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC)","volume":"38","author":"Hussain","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.014_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2326-6066.CIR-14-0209","article-title":"Tumors: wounds that do not heal\u2014redux","volume":"3","author":"Dvorak","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821002128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821002128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:09:52Z","timestamp":1759583392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283821002128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0302283821002128"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2021.03.014","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}